Why Quality Oversight Shouldn’t Be Reactive
Insights
- Home
- Insights
Why Quality Oversight Shouldn’t Be Reactive
Strengthening Data Integrity through Prevention and Precision in 2026 In the fast-paced environment of 2026 clinical research, waiting for an audit to find a mistake is a risk no sponsor can afford. Traditional "reactive" oversight—where issues...
Why Most Feasibility Data Can’t Be Trusted
Overcoming Inflation and Inaccuracy with Real-World Precision in 2026 In the current landscape of 2026 clinical research, the "feasibility questionnaire" is often a source of fiction rather than fact. Traditionally, sites have felt pressured to over-promise...
Why “Recruitment Support” Often Fails at the Site Level
Moving Beyond Generic Ads to Strategic Site Integration in 2026 In 2026, the clinical research industry is facing a paradox: while pharmaceutical sponsors are spending more than ever on third-party "recruitment support," sites are still struggling...